On the other hand, ramucirumab is a human IgG1 monoclonal antibody targeting Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and it is the first biological treatment given as a single drug that has survival benefits in patients with HER2 negative AGC or GEJ adenocarcinoma progressing after first-line chemotherapy. Here, KDR is linked to gastroesophageal junction adenocarcinoma.